Valuation: Renata PLC

Market Cap 51.09B 415M 370M 346M 314M 591M 40.11B 596M 4.15B 1.62B 20.4B 1.56B 1.52B 65.57B P/E 2026 *
18.2x
P/E 2027 * 12.3x
Enterprise Value 51.09B 415M 370M 346M 314M 591M 40.11B 596M 4.15B 1.62B 20.4B 1.56B 1.52B 65.57B EV / Sales 2026 *
1.08x
EV / Sales 2027 * 0.93x
Free-Float
17.05%
Yield 2026 *
1.28%
Yield 2027 * 3.28%
1 week-0.98%
Current month-2.27%
1 month-4.42%
3 months-4.42%
6 months+7.84%
Current year+13.09%
1 week 442
Extreme 442
458
1 month 442
Extreme 442
469.9
Current year 381.8
Extreme 381.8
488
1 year 372
Extreme 372
488
3 years 372
Extreme 372
1,217.9
5 years 372
Extreme 372
1,289.72
10 years 372
Extreme 372
1,289.72
Manager TitleAgeSince
Chief Executive Officer - 31/12/2001
Director of Finance/CFO - -
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member - 31/12/2001
Chairman 84 -
Director/Board Member - 26/08/2013
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-0.98%-7.36%-63.62% 415M
-0.89%+2.73%+40.91%+110.31% 1,060B
-0.40%-2.38%+36.83%+63.95% 623B
-0.26%+3.73%+16.55%+83.05% 480B
-0.65%-1.73%+62.98%+37.46% 352B
-1.17%+2.01%+22.21%+41.92% 345B
-0.87%+1.00%+11.96%+35.30% 274B
-0.74%-1.47%-5.32%+11.46% 249B
-0.80%-2.00%+39.77%+54.44% 223B
-0.50%-1.48%+25.75%+96.48% 182B
Average -0.57%-0.66%+24.43%+47.08% 378.84B
Weighted average by Cap. -0.62%+0.04%+31.57%+70.33%

Financials

2026 *2027 *
Net sales 47.45B 385M 344M 321M 292M 549M 37.25B 553M 3.86B 1.51B 18.95B 1.45B 1.41B 60.91B 55.08B 447M 399M 373M 339M 638M 43.25B 642M 4.48B 1.75B 21.99B 1.68B 1.64B 70.7B
Net income 2.81B 22.82M 20.39M 19.02M 17.28M 32.54M 2.21B 32.78M 229M 89.3M 1.12B 85.67M 83.81M 3.61B 4.39B 35.61M 31.82M 29.68M 26.96M 50.78M 3.44B 51.16M 357M 139M 1.75B 134M 131M 5.63B
Net Debt - -
Projected Income Statement - Annual - Renata PLC
Logo Renata PLC
Renata PLC is a Bangladesh-based pharmaceutical company. The Company is engaged in the manufacturing, marketing and distribution of pharmaceuticals, animal health products, oncology-based products, agro-based products, poultry products, and consumer products. It operates in several modalities, such as oral solids dosage forms, which include tablets, capsules, OROS, oral dispersible tablets; soft gels injectables, which include hormone injectables, general injectables and oncology injectables; inhalers, which include DPI and MDI, and nutraceutical products. Its offering includes anthelmintic, live vaccines, nutrition products, vitamins & minerals, anti-gout, anti-spasmodic, and anti-allergic. The Company has approximately 14 manufacturing facilities spread over three manufacturing sites.
Employees
8,366
Date Price Change Volume
07/10/26 BDT 445.40 +0.52% 5,019
06/10/26 BDT 443.10 0.00% 7,520
05/10/26 BDT 443.10 -0.34% 6,820
04/10/26 BDT 444.60 -0.91% 12,486
01/10/26 BDT 448.70 -1.04% 14,879
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Ratings Surperformance© - Renata PLC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
445.40BDT
Average target price
615.05BDT
Spread / Average Target
+38.09%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Renata PLC
  1. Stock Market
  2. Stocks
  3. RENATA Stock